Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Osmotica Pharmaceuticals plc | osmt-20201231ex32258f297.htm |
| EX-32.1 - EX-32.1 - Osmotica Pharmaceuticals plc | osmt-20201231ex321953c24.htm |
| EX-31.2 - EX-31.2 - Osmotica Pharmaceuticals plc | osmt-20201231ex312bc27dd.htm |
| EX-31.1 - EX-31.1 - Osmotica Pharmaceuticals plc | osmt-20201231ex3113fd9c7.htm |
| EX-21.1 - EX-21.1 - Osmotica Pharmaceuticals plc | osmt-20201231ex211ae34ba.htm |
| EX-10.25 - EX-10.25 - Osmotica Pharmaceuticals plc | osmt-20201231ex102511c8a.htm |
| EX-4.4 - EX-4.4 - Osmotica Pharmaceuticals plc | osmt-20201231ex44a3bea72.htm |
| EX-4.2 - EX-4.2 - Osmotica Pharmaceuticals plc | osmt-20201231ex42947309e.htm |
| 10-K - 10-K - Osmotica Pharmaceuticals plc | osmt-20201231x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-3 No. 333-236193), and |
| (2) | Registration Statement (Form S-8 No. 333-228045; |
of our report dated March 30, 2021, with respect to the consolidated financial statements of Osmotica Pharmaceuticals plc included in this Annual Report (Form 10-K) of Osmotica Pharmaceuticals plc for the year ended December 31, 2020.
/s/Ernst & Young LLP
Iselin, New Jersey
March 30, 2021